How InflaRx N.V. plans to challenge avacopan in ANCA-associated vasculitis with izicopan
InflaRx N.V. is expanding izicopan into renal inflammation and vasculitis markets. Discover what this means for complement inhibitor competition.
How Hansa Biopharma is targeting a transplant blind spot with Imlifidase
Hansa Biopharma AB has submitted a Biologics License Application to the U.S. Food and Drug Administration for imlifidase as a desensitization treatment in highly sensitized adult patients awaiting deceased donor kidney transplants. The submission is supported by the pivotal Phase 3 ConfIdeS trial, and the company is seeking a priority review that could lead to […]